标题
PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology
作者
关键词
-
出版物
Biomedicines
Volume 9, Issue 7, Pages 793
出版商
MDPI AG
发表日期
2021-07-08
DOI
10.3390/biomedicines9070793
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- PCSK9 mediates the oxidative low‑density lipoprotein‑induced pyroptosis of vascular endothelial cells via the UQCRC1/ROS pathway
- (2021) Junfa Zeng et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Impact of PCSK9 on CTRP9-Induced Metabolic Effects in Adult Rat Cardiomyocytes
- (2021) Susanne Rohrbach et al. Frontiers in Physiology
- New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects
- (2021) Qidi Ying et al. Frontiers in Physiology
- PCSK9: a view beyond the canonical cholesterol lowering impact
- (2021) Chiara Macchi et al. AMERICAN JOURNAL OF PATHOLOGY
- Impact of Obesity-Induced Inflammation on Cardiovascular Diseases (CVD)
- (2021) Gopi Battineni et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- PCSK9 genetic (rs11591147) and epigenetic (DNA methylation) modifications associated with PCSK9 expression & serum proteins in CAD patients
- (2021) Nivas Shyamala et al. JOURNAL OF GENE MEDICINE
- In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates
- (2021) Kiran Musunuru et al. NATURE
- In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels
- (2021) Tanja Rothgangl et al. NATURE BIOTECHNOLOGY
- New PCSK9 inhibitor miR-552-3p reduces LDL-C via enhancing LDLR in high fat diet-fed mice
- (2021) Ningning Ma et al. PHARMACOLOGICAL RESEARCH
- An oral antisense oligonucleotide for PCSK9 inhibition
- (2021) Peter Gennemark et al. Science Translational Medicine
- PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
- (2021) Aureli Luquero et al. Frontiers in Cardiovascular Medicine
- PCSK9 Biology and Its Role in Atherothrombosis
- (2021) Cristina Barale et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice
- (2021) Xiaoding Xu et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Critical Role of LOX-1-PCSK9 Axis in the Pathogenesis of Atheroma Formation and Its Instability
- (2021) Jonathan Tam et al. Heart Lung and Circulation
- In Silico Insights into Protein–Protein Interaction Disruptive Mutations in the PCSK9-LDLR Complex
- (2020) William R. Martin et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Role of PCSK9 in the course of ejection fraction change after ST-segment elevation myocardial infarction: a pilot study
- (2020) Gema Miñana et al. ESC Heart Failure
- Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1
- (2020) Ulf Landmesser et al. CARDIOVASCULAR RESEARCH
- Naturally Occurring PCSK9 Inhibitors
- (2020) Maria Pia Adorni et al. Nutrients
- PCSK9 Protein and rs562556 Polymorphism Are Associated With Arterial Plaques in Healthy Middle‐Aged Population: The STANISLAS Cohort
- (2020) João Pedro Ferreira et al. Journal of the American Heart Association
- Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE Study
- (2020) Nicola Ferri et al. ATHEROSCLEROSIS
- PCSK9Qβ-003 Vaccine Attenuates Atherosclerosis in Apolipoprotein E-Deficient Mice
- (2020) Danyu Wu et al. CARDIOVASCULAR DRUGS AND THERAPY
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders
- (2020) Emma M. O’Connell et al. Frontiers in Neuroscience
- PCSK9 and LRP5 in macrophage lipid internalization and inflammation
- (2020) Lina Badimon et al. CARDIOVASCULAR RESEARCH
- Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall
- (2020) Yanan Guo et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Loss-of-function mutation of PCSK9 as a protective factor in the clinical expression of familial hypercholesterolemia
- (2020) Ane Bayona et al. MEDICINE
- PCSK9 and atherosclerosis: Looking beyond LDL regulation
- (2020) Rosetta Ragusa et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- The loss-of-function PCSK9Q152H variant increases ER chaperones GRP78 and GRP94 and protects against liver injury
- (2020) Paul F. Lebeau et al. JOURNAL OF CLINICAL INVESTIGATION
- Kidney-derived PCSK9—a new driver of hyperlipidemia in nephrotic syndrome?
- (2020) Ferruh Artunc KIDNEY INTERNATIONAL
- PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
- (2020) Julius L. Katzmann et al. Frontiers in Physiology
- microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production
- (2020) Jianjie Dong et al. JCI Insight
- In vitro selection generates RNA aptamer that antagonizes PCSK9–LDLR interaction and recovers cellular LDL uptake
- (2020) Takehiro Ando et al. JOURNAL OF BIOSCIENCE AND BIOENGINEERING
- PCSK9 levels do not predict severity and recurrence of cardiovascular events in patients with acute myocardial infarction
- (2020) Marianne Zeller et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Genetic Inhibition of PCSK9 and Liver Function
- (2020) Antoine Rimbert et al. JAMA Cardiology
- PCSK9 is Expressed in Human Visceral Adipose Tissue and Regulated by Insulin and Cardiac Natriuretic Peptides
- (2019) Marica Bordicchia et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Sex Differences Associated With Circulating PCSK9 in Patients Presenting With Acute Myocardial Infarction
- (2019) Zhong Zhang et al. Scientific Reports
- A review on coronary artery disease, its risk factors, and therapeutics
- (2019) Arup Kr. Malakar et al. JOURNAL OF CELLULAR PHYSIOLOGY
- The immune functions of PCSK9: Local and systemic perspectives
- (2019) Xing Liu et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Resveratrol downregulates PCSK9 expression and attenuates steatosis through estrogen receptor α-mediated pathway in L02 cells
- (2019) Yi Jing et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Low LDL Cholesterol by PCSK9 Variation Reduces Cardiovascular Mortality
- (2019) Marianne Benn et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PCSK9 hapten multicopy displayed onto Carrier Protein nanoparticle: an anti-atherosclerosis vaccine
- (2019) Shasha You et al. ACS Biomaterials-Science & Engineering
- PCSK9: from molecular biology to clinical applications
- (2019) Jonathan Malo et al. ANNALS OF CLINICAL BIOCHEMISTRY
- Targeting PCSK9: Implications for basic science and upcoming challenges
- (2019) Toshiyuki Nishikido et al. BRITISH JOURNAL OF PHARMACOLOGY
- PCSK9 and atherosclerosis burden in the coronary arteries of patients undergoing coronary angiography
- (2019) Yunes Panahi et al. CLINICAL BIOCHEMISTRY
- PCSK9 Antibody Alirocumab Attenuates Arterial Wall Inflammation Without Changes in Circulating Inflammatory Markers
- (2019) Renate M. Hoogeveen et al. JACC-Cardiovascular Imaging
- The Arg499His gain-of-function mutation in the C-terminal domain of PCSK9
- (2019) Rosa M. Sánchez-Hernández et al. ATHEROSCLEROSIS
- Blood flow patterns regulate PCSK9 secretion via MyD88-mediated pro-inflammatory cytokines
- (2019) Shijie Liu et al. CARDIOVASCULAR RESEARCH
- PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1
- (2019) Zufeng Ding et al. CARDIOVASCULAR RESEARCH
- Efficacy and safety of PCSK9 monoclonal antibodies
- (2019) Zohaib Iqbal et al. Expert Opinion On Drug Safety
- Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations
- (2019) Paul N. Hopkins et al. Journal of Clinical Lipidology
- Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
- (2019) Ye-Xuan Cao et al. Journal of Translational Medicine
- CTRP9 Ameliorates Atrial Inflammation, Fibrosis, and Vulnerability to Atrial Fibrillation in Post‐Myocardial Infarction Rats
- (2019) Mingxin Liu et al. Journal of the American Heart Association
- Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis
- (2019) Amir Abbas Momtazi-Borojeni et al. BMC Medicine
- Ectopic Expression of PCSK9 by Smooth Muscle Cells Contributes to Aortic Dissection
- (2018) Yasunori Iida et al. ANNALS OF VASCULAR SURGERY
- Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism
- (2018) Sheng-Hua Yang et al. Cardiovascular Diabetology
- PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages
- (2018) Zufeng Ding et al. CARDIOVASCULAR RESEARCH
- PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy
- (2018) Zufeng Ding et al. CARDIOVASCULAR RESEARCH
- PCSK9
- (2018) Michael D. Shapiro et al. CIRCULATION RESEARCH
- Evaluation of PCSK9 levels and its genetic polymorphisms in women with polycystic ovary syndrome
- (2018) Luana B. Xavier et al. GENE
- Loss-of-function PCSK9 mutants evade the unfolded protein response sensor GRP78 and fail to induce endoplasmic reticulum stress when retained
- (2018) Paul Lebeau et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- R46L polymorphism in the PCSK9 gene: Relationship to lipid levels, subclinical vascular disease, and erectile dysfunction
- (2018) Jose M. Mostaza et al. Journal of Clinical Lipidology
- The Evolving Future of PCSK9 Inhibitors
- (2018) Robert S. Rosenson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Peripheral vascular atherosclerosis in a novel PCSK9 gain-of-function mutant Ossabaw miniature pig model
- (2018) Ahmad F. Hedayat et al. Translational Research
- PCSK9 induces a pro-inflammatory response in macrophages
- (2018) Chiara Ricci et al. Scientific Reports
- Ossabaw Pigs With a PCSK9 Gain‐of‐Function Mutation Develop Accelerated Coronary Atherosclerotic Lesions: A Novel Model for Preclinical Studies
- (2018) Fang Yuan et al. Journal of the American Heart Association
- PCSK9 R496W (rs374603772) and D374Y (rs137852912) mutations in Turkish patients with primary dyslipidemia
- (2018) Zuhal Eroglu Anatolian Journal of Cardiology
- C679X loss-of-function PCSK9 variant lowers fasting glucose levels in a black South African population: A longitudinal study
- (2018) Tinashe Chikowore et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- PCSK9 Involvement in Aortic Valve Calcification
- (2018) Paolo Poggio et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Inhibiting PCSK9 — biology beyond LDL control
- (2018) Robert M. Stoekenbroek et al. Nature Reviews Endocrinology
- PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia
- (2017) Sophie J. Bernelot Moens et al. EUROPEAN HEART JOURNAL
- The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
- (2017) Christine Landlinger et al. EUROPEAN HEART JOURNAL
- Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study
- (2017) Eliano P. Navarese et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- PCSK9 and Atherosclerosis - Lipids and Beyond
- (2017) Michael D. Shapiro et al. Journal of Atherosclerosis and Thrombosis
- The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response
- (2017) Teik Chye Ooi et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Genetic variants influencing lipid levels and risk of dyslipidemia in Chinese population
- (2017) Huaichao Luo et al. JOURNAL OF GENETICS
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- PCSK 9 gain-of-function mutations (R496W and D374Y) and clinical cardiovascular characteristics in a cohort of Turkish patients with familial hypercholesterolemia
- (2017) Esra Kaya Anatolian Journal of Cardiology
- PCSK9 signaling pathways and their potential importance in clinical practice
- (2017) Michał Wiciński et al. EPMA Journal
- Sortilin and Its Multiple Roles in Cardiovascular and Metabolic Diseases
- (2017) Claudia Goettsch et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Rare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol levels
- (2017) Chan Joo Lee et al. PLoS One
- Identification and in vitro characterization of two new PCSK9 Gain of Function variants found in patients with Familial Hypercholesterolemia
- (2017) Maria Donata Di Taranto et al. Scientific Reports
- Cross-Talk Between PCSK9 and Damaged mtDNA in Vascular Smooth Muscle Cells: Role in Apoptosis
- (2016) Zufeng Ding et al. ANTIOXIDANTS & REDOX SIGNALING
- Hypercholesterolemia Induced by a PCSK9 Gain-of-Function Mutation Augments Angiotensin II–Induced Abdominal Aortic Aneurysms in C57BL/6 Mice—Brief ReportHighlights
- (2016) Hong Lu et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement
- (2016) Nicola Ferri et al. ATHEROSCLEROSIS
- A single injection of gain-of-function mutant PCSK9 adeno-associated virus vector induces cardiovascular calcification in mice with no genetic modification
- (2016) Claudia Goettsch et al. ATHEROSCLEROSIS
- Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis
- (2016) Charalambos Vlachopoulos et al. ATHEROSCLEROSIS
- Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms
- (2016) Hagai Tavori et al. CARDIOVASCULAR RESEARCH
- Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering
- (2016) Giuseppe Danilo Norata et al. CARDIOVASCULAR RESEARCH
- PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis
- (2016) Anne Langsted et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- 60 YEARS OF POMC: From the prohormone theory to pro-opiomelanocortin and to proprotein convertases (PCSK1 to PCSK9)
- (2016) Michel Chrétien et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease
- (2016) Tsuyoshi Nozue et al. Lipids in Health and Disease
- Analysis of the association between plasma PCSK9 and Lp(a) in Han Chinese
- (2016) S.-H. Yang et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain
- (2016) Steve Poirier et al. PLoS One
- Hemodynamic Shear Stress via ROS Modulates PCSK9 Expression in Human Vascular Endothelial and Smooth Muscle Cells and Along the Mouse Aorta
- (2015) Zufeng Ding et al. ANTIOXIDANTS & REDOX SIGNALING
- PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse LiverSignificance
- (2015) Annie Demers et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
- (2015) Rainer Schulz et al. BASIC RESEARCH IN CARDIOLOGY
- Cross-talk between LOX-1 and PCSK9 in vascular tissues
- (2015) Zufeng Ding et al. CARDIOVASCULAR RESEARCH
- Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia
- (2015) Karim Si-Tayeb et al. Disease Models & Mechanisms
- LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153–421): Design, synthesis and biochemical evaluation
- (2015) Rasha H. Alghamdi et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- The Relationship between the Plasma PCSK9 Levels and Platelet Indices in Patients with Stable Coronary Artery Disease
- (2015) Sha Li et al. Journal of Atherosclerosis and Thrombosis
- Local effects of human PCSK9 on the atherosclerotic lesion
- (2015) Ilaria Giunzioni et al. JOURNAL OF PATHOLOGY
- Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat
- (2015) Yan Zhang et al. BMC Cardiovascular Disorders
- Sorting an LDL receptor with bound PCSK9 to intracellular degradation
- (2014) Trond P. Leren ATHEROSCLEROSIS
- The Hypercholesterolemia-Risk Gene SORT1 Facilitates PCSK9 Secretion
- (2014) Camilla Gustafsen et al. Cell Metabolism
- PCSK9
- (2014) Nabil G. Seidah et al. CIRCULATION RESEARCH
- The effect of insulin on circulating PCSK9 in postmenopausal obese women
- (2014) Zuhier Awan et al. CLINICAL BIOCHEMISTRY
- PCSK9 and LDLR degradation
- (2014) Thomas A. Lagace CURRENT OPINION IN LIPIDOLOGY
- PCSK9 acts as a chaperone for the LDL receptor in the endoplasmic reticulum
- (2013) Thea Bismo Strøm et al. BIOCHEMICAL JOURNAL
- Association between PCSK9 and LDLR gene polymorphisms with coronary heart disease: Case-control study and meta-analysis
- (2013) Lina Zhang et al. CLINICAL BIOCHEMISTRY
- FoxO3 Transcription Factor and Sirt6 Deacetylase Regulate Low Density Lipoprotein (LDL)-cholesterol Homeostasis via Control of the Proprotein Convertase Subtilisin/Kexin Type 9 (Pcsk9) Gene Expression
- (2013) Rongya Tao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
- (2013) Kevin Fitzgerald et al. LANCET
- Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations
- (2013) Janice Mayne et al. Lipids in Health and Disease
- Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia
- (2012) Marianne Abifadel et al. ATHEROSCLEROSIS
- PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages
- (2012) ZHIHAN TANG et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- The M2 Module of the Cys-His-rich Domain (CHRD) of PCSK9 Protein Is Needed for the Extracellular Low-density Lipoprotein Receptor (LDLR) Degradation Pathway
- (2012) Yascara Grisel Luna Saavedra et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The biology and therapeutic targeting of the proprotein convertases
- (2012) Nabil G. Seidah et al. NATURE REVIEWS DRUG DISCOVERY
- Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue
- (2011) Anna Roubtsova et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
- (2011) Nicola Ferri et al. ATHEROSCLEROSIS
- Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor
- (2011) Øystein L. Holla et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Circulating Proprotein Convertase Subtilisin Kexin Type 9 Has a Diurnal Rhythm Synchronous With Cholesterol Synthesis and Is Reduced by Fasting in Humans
- (2010) Lena Persson et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population
- (2010) Qin Cui et al. ATHEROSCLEROSIS
- Plasma proprotein convertase subtilisin–kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients
- (2010) Paul J.W.H. Kappelle et al. ATHEROSCLEROSIS
- Regulation of the proprotein convertase subtilisin/kexin type 9 in intestinal epithelial cells
- (2009) François Leblond et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles
- (2009) Giuseppe Danilo Norata et al. ATHEROSCLEROSIS
- PCSK9 is expressed in pancreatic δ-cells and does not alter insulin secretion
- (2009) Cédric Langhi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants
- (2009) Sekar Kathiresan et al. NATURE GENETICS
- Berberine decreases PCSK9 expression in HepG2 cells
- (2008) Jamie Cameron et al. ATHEROSCLEROSIS
- Degradation of LDLR protein mediated by ‘gain of function’ PCSK9 mutants in normal and ARH cells
- (2008) Tommaso Fasano et al. ATHEROSCLEROSIS
- Self-Association of Human PCSK9 Correlates with Its LDLR-Degrading Activity†
- (2008) Daping Fan et al. BIOCHEMISTRY
- Characterization of novel mutations in the catalytic domain of the PCSK9 gene
- (2008) J. Cameron et al. JOURNAL OF INTERNAL MEDICINE
- Functional analysis of sites within PCSK9 responsible for hypercholesterolemia
- (2008) Shilpa Pandit et al. JOURNAL OF LIPID RESEARCH
- Familial hypercholesterolaemia in Portugal
- (2007) M. Bourbon et al. ATHEROSCLEROSIS
- Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa
- (2007) Vivienne M. Homer et al. ATHEROSCLEROSIS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now